Genetic health screening startup Color Genomics is in the final stages of allocations for an $80 million Series C financing round, TechCrunch has confirmed with the company.
Axios first spotted Color had raised $52 million so far in a recent SEC filing. The company has since told TechCrunch it will soon be closing on $80 million in financing led by General Catalyst, which led Color’s previous Series B round.
Other investors in this latest round include Laurene Powell Job’s Emerson Collective and CRV.
Color is similar to other genetics startups, like 23andMe and Ancestry, in that it provides information to you based on the DNA given in a spit tube test. It’s main focus has been in providing a series of genetic cancer screenings in an at-home kit.
The company recently launched a test for hereditary high cholesterol as an indication for possible heart disease and says it plans to release more genetic health screening kits in the future. Color tells us this new round of funding will help get it there.
“This new funding will enable Color to continue developing new tests for hereditary conditions where the science is clear and the results are actionable — and new services that help our clients proactively manage their own health,” co-founder and CEO Othman Laraki told TechCrunch.
Color had raised a total of $98.5 million before this round, bringing the total to $179 million in venture capital raised thus far.
